GlassScriptPhysician profile
Julie Thao
NPI 1689264418
$2,552.75
in general payments reported to CMS, 2019-2025
17 companies · $1,004 in 2025
The $1,004 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $237 · 2023: $903 · 2024: $409 · 2025: $1,004.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,316.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,315.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $460.56 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $312.68 | 2023-2025 | Airsupra, Tezspire, Breztri |
| Amgen INC. | $290.52 | 2023-2025 | Otezla, Repatha, Tezspire |
| Intercept Pharmaceuticals, INC. | $231.34 | 2021-2023 | Ocaliva |
| Pfizer INC. | $185.64 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $182.68 | 2023-2025 | |
| Vertos Medical, INC. | $164.76 | 2024 | Mild Device Kit |
| Lilly USA, LLC | $142.89 | 2023-2025 | Mounjaro |
| Neurocrine Biosciences, INC. | $140.00 | 2023 | Ingrezza |
| Madrigal Pharmaceuticals | $123.86 | 2024 | Rezdiffra |
| Corcept Therapeutics | $115.00 | 2025 | Korlym |
| Dexcom, INC. | $80.33 | 2023-2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $32.28 | 2025 | The Cologuard Plus Collection Kit |
| Abbvie INC. | $27.68 | 2025 | |
| Mannkind Corporation | $25.13 | 2025 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.20 | 2025 | Caplyta |
| Cranial Technologies, INC | $15.20 | 2025 | Doc Band |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Thao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.